Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases

Jilu Zhang, Alan Hodges, Shu Hsia Chen, Ping Ying Pan

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells, which have been characterized for their immunosuppressive capacity through multiple mechanisms. These cells have been extensively studied in the field of tumor immunity. Emerging evidence has highlighted its essential role in maintaining immune tolerance in transplantation and autoimmunity. Because of their robust immune inhibitory activities, there has been growing interest in MDSC-based cellular therapy. Various pre-clinical studies have demonstrated that the adoptive transfer of MDCS represented a promising therapeutic strategy for immune-related disorders. In this review, we summarize relevant studies of MDSC-based cell therapy in transplantation and autoimmune diseases and discuss the challenges and future directions for clinical application of MDSC-based cell therapy.

Original languageEnglish (US)
Article number104300
JournalCellular Immunology
StatePublished - Apr 2021


  • Autoimmune disease
  • Cellular therapy
  • Myeloid-derived suppressor cell
  • Transplantation

ASJC Scopus subject areas

  • Immunology


Dive into the research topics of 'Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases'. Together they form a unique fingerprint.

Cite this